ITERUM THERAPEUTICS ($ITRM) posted quarterly earnings results on Friday, February 7th. The company reported earnings of -$0.12 per share, beating estimates of -$0.22 by $0.10. The company also reported revenue of $0, equaling estimates of $0 by $0.
You can see Quiver Quantitative's $ITRM stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
ITERUM THERAPEUTICS Hedge Fund Activity
We have seen 11 institutional investors add shares of ITERUM THERAPEUTICS stock to their portfolio, and 6 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ARMISTICE CAPITAL, LLC added 1,340,000 shares (+inf%) to their portfolio in Q3 2024, for an estimated $1,460,600
- NEW LEAF VENTURE PARTNERS, L.L.C. added 247,934 shares (+255.4%) to their portfolio in Q3 2024, for an estimated $270,248
- ALPINE GLOBAL MANAGEMENT, LLC added 64,833 shares (+inf%) to their portfolio in Q3 2024, for an estimated $70,667
- RENAISSANCE TECHNOLOGIES LLC removed 64,022 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $69,783
- SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 38,483 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $41,946
- XTX TOPCO LTD added 33,040 shares (+inf%) to their portfolio in Q3 2024, for an estimated $36,013
- APOLLON FINANCIAL, LLC added 25,500 shares (+11.3%) to their portfolio in Q4 2024, for an estimated $45,135
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
